Orient Pharma Co., Ltd. - Laporan Laba Rugi (TTM)

Orient Pharma Co., Ltd.
TW ˙ TPEX
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Orient Pharma Co., Ltd. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 412 412 419 427 451 463 520 576 544 512 578 644 767 890 952 1,066 1,144 1,223 1,264 1,262
Change (%) 0.08 1.79 1.76 5.71 2.71 12.20 10.88 -5.60 -5.93 12.91 11.43 19.09 16.03 7.00 11.91 7.37 6.87 3.35 -0.12
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 352 337 331 326 329 321 344 368 362 357 366 375 398 421 433 480 526 571 607 598
Change (%) -4.36 -1.63 -1.66 0.95 -2.52 7.34 6.84 -1.53 -1.55 2.65 2.58 6.11 5.76 2.75 11.00 9.45 8.63 6.32 -1.59
% of Revenue 85.55 81.76 79.01 76.36 72.92 69.21 66.21 63.80 66.55 69.65 63.32 58.29 51.93 47.34 45.45 45.08 45.96 46.72 48.06 47.35
Gross Operating Profit 59 75 88 101 122 143 176 209 182 155 212 269 369 469 519 585 618 652 656 665
Change (%) 26.36 17.13 14.62 21.06 16.81 23.13 18.79 -12.78 -14.65 36.45 26.72 37.24 27.13 10.83 12.67 5.67 5.36 0.75 1.24
% of Revenue 14.45 18.24 20.99 23.64 27.08 30.79 33.79 36.20 33.45 30.35 36.68 41.71 48.07 52.66 54.55 54.92 54.04 53.28 51.94 52.65
SG&A 60 58 58 57 57 56 56 56 62 68 140 212 278 344 355 357 374 390 383 412
Change (%) -2.60 -0.62 -0.63 -1.02 -0.39 -0.08 -0.08 10.18 9.24 106.15 51.49 31.30 23.84 3.07 0.65 4.56 4.36 -1.79 7.59
% of Revenue 14.46 14.07 13.74 13.41 12.56 12.18 10.85 9.78 11.41 13.25 24.20 32.89 36.27 38.71 37.28 33.53 32.65 31.89 30.30 32.64
R&D 155 184 213 242 242 220 191 163 146 129 122 115 107 100 93 84 94 104 102 108
Change (%) 18.72 15.87 13.69 -0.27 -9.08 -12.97 -14.91 -10.28 -11.46 -5.49 -5.81 -6.59 -7.05 -7.41 -9.33 11.83 10.58 -1.81 6.27
% of Revenue 37.63 44.64 50.82 56.78 53.57 47.42 36.78 28.23 26.83 25.25 21.14 17.87 14.01 11.23 9.71 7.87 8.20 8.48 8.06 8.57
OpEx 567 579 602 625 627 597 592 587 570 554 628 702 784 866 880 922 993 1,065 1,092 1,118
Change (%) 2.13 4.03 3.87 0.30 -4.86 -0.84 -0.85 -2.83 -2.91 13.43 11.84 11.63 10.42 1.70 4.69 7.77 7.21 2.56 2.36
% of Revenue 137.64 140.47 143.56 146.55 139.05 128.81 113.84 101.80 104.79 108.15 108.65 109.05 102.21 97.27 92.45 86.49 86.81 87.09 86.42 88.57
Operating Income -155 -167 -183 -199 -176 -133 -72 -10 -26 -42 -50 -58 -17 24 72 144 151 158 172 144
Change (%) 7.60 9.56 8.73 -11.31 -24.23 -46.11 -85.57 151.06 60.17 19.83 16.55 -70.86 -243.17 195.67 100.30 4.82 4.60 8.69 -15.90
% of Revenue -37.64 -40.47 -43.56 -46.55 -39.05 -28.81 -13.84 -1.80 -4.79 -8.15 -8.65 -9.05 -2.21 2.73 7.55 13.51 13.19 12.91 13.58 11.43
Interest Expense -6 -5 -5 -5 -5 -6 -6 -6 -7 -7 -9 -11 -12 -14 -14 -14 -14 -14 -13 -12
Change (%) -5.62 -4.14 -4.32 6.79 8.24 5.76 5.45 7.99 7.40 21.26 17.54 16.13 13.89 3.36 -0.45 -1.17 -1.18 -6.50 -5.50
% of Revenue -1.38 -1.31 -1.23 -1.16 -1.17 -1.23 -1.16 -1.10 -1.26 -1.44 -1.55 -1.63 -1.59 -1.56 -1.51 -1.34 -1.24 -1.14 -1.03 -0.98
Net Income -162 -171 -172 -173 -170 -103 -62 -21 -25 -29 -38 -48 -13 22 60 119 113 107 120 80
Change (%) 5.66 0.53 0.53 -1.83 -39.63 -39.60 -65.55 17.32 14.77 33.60 25.15 -73.18 -272.81 170.08 97.85 -4.92 -5.18 11.70 -33.54
% of Revenue -39.40 -41.59 -41.08 -40.59 -37.69 -22.15 -11.93 -3.71 -4.61 -5.62 -6.65 -7.47 -1.68 2.50 6.32 11.18 9.90 8.78 9.49 6.31

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista